Bioworld Technology, China  

Bioworld Technology offers an extensive portfolio comprising more than 30,000 primary antibodies, T-cell and B-cell surface proteins, COVID-19 and infectious disease–related products, secondary antibodies, plasmids and vectors, cytokines and recombinant proteins, ELISA kits, antigen peptides, diagnostic kits, in vitro diagnostic antigens and antibodies, and pre-cut test sheets.